Document is current

Any future updates will be listed below

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry

Crossref DOI link: https://doi.org/10.1186/s13075-017-1496-5

Published Online: 2018-01-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark